Concepedia

Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice

Massimo Breccia, Elisabetta Abruzzese, Fausto Castagnetti, Massimiliano Bonifacio, Domenica Gangemi, Federica Sorà, Alessandra Iurlo, Luigiana Luciano, Antonella Gozzini, Massimo Gentile,

Annals of Hematology · 2018 · 40 citations · 3 references

DOI

Concepts

References

3

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

Jörge E. Cortes, D. W. Kim, Javier Pinilla‐Ibarz et al. · New England Journal of Medicine · 2013 · 1.1K citations · Full text

, , +17

Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial

Jörge E. Cortes, Dong‐Wook Kim, Javier Pinilla‐Ibarz et al. · Blood · 2014 · 59 citations

, , +7

Clinical impact of dose modification and dose intensity on response to ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias.

Andreas Hochhaus, Javier Pinilla‐Ibarz, Dong‐Wook Kim et al. · Journal of Clinical Oncology · 2014 · 21 citations

, , +13